The contract research organization (CRO) IRBM has signed a new agreement with Merck & Co (NYSE: MRK) to continue their collaboration in the peptide therapeutics area.
In recent years, significant advances have been made in peptide discovery through the well-established phage and mRNA display platforms, and with major progress achieved for half-life extension strategies and the use of formulation enhancers to support oral route administration.
"IRBM’s first-class scientific expertise in peptide design and synthesis combined with Merck’s exceptional drug development capabilities"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze